Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria~2. Not in MDA at the time of screening~3. Has 3 or more tender and 3 or more swollen joints~4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks~Exclusion Criteria:~1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients~2. History of methotrexate intolerance/toxicity~3. Medical conditions(s) precluding methotrexate dose increase above 15 mg~4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
- Part 1: ADA + MTX (Type: EXPERIMENTAL): Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
- Part 2: MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
- Part 2: ADA + MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
- Part 2: ADA (Type: EXPERIMENTAL): Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
- Part 2: ADA ew + MTX (Type: EXPERIMENTAL): Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew

Based on this trial design, predict the completion outcome and termination type (if applicable).